Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)

(2010) T. P. Hughes et al.   BLOOD

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

(2010) François-Xavier Mahon et al.   LANCET ONCOLOGY

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

(2010) Hagop Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations

(2009) M. C. Muller et al.   BLOOD

Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors

(2009) S. Soverini et al.   BLOOD

Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy

(2009) A. Quintas-Cardama et al.   BLOOD

Results of Dasatinib Therapy in Patients With Early Chronic-Phase Chronic Myeloid Leukemia

(2009) Jorge E. Cortes et al.   JOURNAL OF CLINICAL ONCOLOGY

Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors

(2008) E. Jabbour et al.   BLOOD

European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor

(2008) D. Marin et al.   BLOOD

Treatment of chronic myeloid leukemia in blast crisis

(2008) R. Hehlmann et al.   HAEMATOLOGICA

Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat Analysis

(2008) Hugues de Lavallade et al.   JOURNAL OF CLINICAL ONCOLOGY

Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia

(2007) Hagop Kantarjian et al.   CANCER